Acute Ischemic Stroke - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 130 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Ischemic Stroke - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2016', provides an overview of the Acute Ischemic Stroke pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
- The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
- The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Ischemic Stroke Overview 9
Therapeutics Development 10
Pipeline Products for Acute Ischemic Stroke - Overview 10
Acute Ischemic Stroke - Therapeutics under Development by Companies 11
Acute Ischemic Stroke - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Acute Ischemic Stroke - Products under Development by Companies 16
Acute Ischemic Stroke - Companies Involved in Therapeutics Development 18
AB Science SA 18
AstraZeneca Plc 19
Biogen Inc 20
D-Pharm Ltd. 21
Daiichi Sankyo Company, Limited 22
DiaMedica Inc. 23
Digna Biotech, S.L. 24
Glucox Biotech AB 25
Jeil Pharmaceutical Co., Ltd. 26
Lumosa Therapeutics Co., Ltd. 27
Mitsubishi Tanabe Pharma Corporation 28
Pharmicell Co., Ltd. 29
PhytoHealth Corporation 30
Remedy Pharmaceuticals, Inc. 31
Saneron CCEL Therapeutics, Inc. 32
Simcere Pharmaceutical Group 33
Stemedica Cell Technologies, Inc. 34
Acute Ischemic Stroke - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Target 36
Assessment by Mechanism of Action 39
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
3K3A-APC - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AB-022 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ApTLR-4FT - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Cellgram-IS - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
DB-017 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DM-199 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
DS-1040 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
glyburide - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
HBI-002 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
HBN-1 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
JPI-289 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
LT-3001 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
masitinib - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
MP-124 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
natalizumab - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Neu-2000 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
PHN-014 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Rejuveinix - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
SIM-071201 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Stem Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
THR-18 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
ticagrelor - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
TMS-007 - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
Acute Ischemic Stroke - Dormant Projects 112
Acute Ischemic Stroke - Discontinued Products 115
Acute Ischemic Stroke - Product Development Milestones 117
Featured News & Press Releases 117
Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199 117
Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199 117
Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia 117
Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial 118
Nov 04, 2015: DiaMedica Provides Corporate Update 118
Oct 09, 2015: Remedy Pharmaceuticals' Drug CIRARA™ Cut Death Rates from Severe Stroke by More Than Half 120
Sep 29, 2015: Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting 123
Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference 123
Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA 123
Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA 124
Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA 125
Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA 125
Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures 126
Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients 127
Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA 127
Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 129
Disclaimer 130

List of Tables

Number of Products under Development for Acute Ischemic Stroke, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Development by Companies, H2 2016 (Contd..1) 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Acute Ischemic Stroke - Pipeline by AB Science SA, H2 2016 18
Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2016 19
Acute Ischemic Stroke - Pipeline by Biogen Inc, H2 2016 20
Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2016 21
Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 22
Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2016 23
Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2016 24
Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2016 25
Acute Ischemic Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 26
Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2016 27
Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 28
Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2016 29
Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2016 30
Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016 31
Acute Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2016 32
Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2016 33
Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 34
Assessment by Monotherapy Products, H2 2016 35
Number of Products by Stage and Target, H2 2016 37
Number of Products by Stage and Mechanism of Action, H2 2016 40
Number of Products by Stage and Route of Administration, H2 2016 43
Number of Products by Stage and Molecule Type, H2 2016 45
Acute Ischemic Stroke - Dormant Projects, H2 2016 112
Acute Ischemic Stroke - Dormant Projects (Contd..1), H2 2016 113
Acute Ischemic Stroke - Dormant Projects (Contd..2), H2 2016 114
Acute Ischemic Stroke - Discontinued Products, H2 2016 115
Acute Ischemic Stroke - Discontinued Products (Contd..1), H2 2016 116